GT200300020A - Polimorfismos geneticos en el gen de la preprotaquiquinina - Google Patents

Polimorfismos geneticos en el gen de la preprotaquiquinina

Info

Publication number
GT200300020A
GT200300020A GT200300020A GT200300020A GT200300020A GT 200300020 A GT200300020 A GT 200300020A GT 200300020 A GT200300020 A GT 200300020A GT 200300020 A GT200300020 A GT 200300020A GT 200300020 A GT200300020 A GT 200300020A
Authority
GT
Guatemala
Prior art keywords
gen
preprotaquiquinine
genetic polymorphisms
compatibility
effectiveness
Prior art date
Application number
GT200300020A
Other languages
English (en)
Inventor
Dorothee Foernzler
Lara Hashimoto
Jia Li
Eric Luedin
Andrew Sleght
Pierre Vankan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300020A publication Critical patent/GT200300020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA CORRELACIONAR POLIMORFISMOS DE UN UNICO NUCLEOTIDO EN EL GEN NKNA CON LA EFICACIA Y COMPATIBILIDAD DE UN COMPUESTO FARMACOLOGICAMENTE ACTIVO ADMINISTRADO A UN SER HUMANO. LA INVENCION SE REFIERE ADEMAS A UN METODO PARA DETERMINAR LA EFICACIA Y COMPATIBILIDAD DEL COMPUESTO.
GT200300020A 2002-01-31 2003-01-29 Polimorfismos geneticos en el gen de la preprotaquiquinina GT200300020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02001937 2002-01-31

Publications (1)

Publication Number Publication Date
GT200300020A true GT200300020A (es) 2003-12-23

Family

ID=27635778

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300020A GT200300020A (es) 2002-01-31 2003-01-29 Polimorfismos geneticos en el gen de la preprotaquiquinina

Country Status (21)

Country Link
US (2) US20030158187A1 (es)
EP (1) EP1472377A2 (es)
JP (1) JP2005515788A (es)
KR (1) KR20040077910A (es)
CN (1) CN1625603A (es)
AR (1) AR038334A1 (es)
BR (1) BR0307257A (es)
CA (1) CA2473128A1 (es)
GT (1) GT200300020A (es)
HR (1) HRP20040669A2 (es)
IL (1) IL162733A0 (es)
MX (1) MXPA04007353A (es)
NO (1) NO20043613L (es)
PA (1) PA8564401A1 (es)
PE (1) PE20030816A1 (es)
PL (1) PL371731A1 (es)
RU (1) RU2004126440A (es)
TW (1) TW200302729A (es)
UY (1) UY27634A1 (es)
WO (1) WO2003064685A2 (es)
ZA (1) ZA200405516B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
US9359639B2 (en) 2009-05-26 2016-06-07 Xiamen University Method for the detection of multiple single nucleotide variations or single nucleotide polymorphisms in a single tube
CA2897245A1 (en) * 2013-01-08 2014-07-17 Sphingotec Gmbh A method for predicting the risk of getting cancer or diagnosing cancer in a subject

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613431D0 (en) * 1986-06-03 1986-07-09 Medical Res Council Human tachykinins
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
AU5052599A (en) * 1998-07-25 2000-02-21 Astrazeneca Ab Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases
ATE253561T1 (de) * 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof

Also Published As

Publication number Publication date
WO2003064685A2 (en) 2003-08-07
IL162733A0 (en) 2005-11-20
CN1625603A (zh) 2005-06-08
RU2004126440A (ru) 2005-08-10
HRP20040669A2 (en) 2005-06-30
US20030158187A1 (en) 2003-08-21
BR0307257A (pt) 2004-12-14
NO20043613L (no) 2004-08-30
CA2473128A1 (en) 2003-08-07
UY27634A1 (es) 2003-07-31
PL371731A1 (en) 2005-06-27
EP1472377A2 (en) 2004-11-03
PE20030816A1 (es) 2003-10-28
US20060228752A1 (en) 2006-10-12
MXPA04007353A (es) 2004-11-26
ZA200405516B (en) 2005-07-01
KR20040077910A (ko) 2004-09-07
AR038334A1 (es) 2005-01-12
WO2003064685A3 (en) 2003-12-24
PA8564401A1 (es) 2004-03-26
TW200302729A (en) 2003-08-16
JP2005515788A (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
DK1649017T3 (da) Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
CY1115852T1 (el) Φαρμακευτικες συνθεσεις
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
HN2000000137A (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
LU92202I9 (es)
DK1390371T3 (da) Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
HRP20080452T3 (en) Orally disintegrating pharmaceutical composition comprising risperidone
PA8571901A1 (es) Nueva composicion farmaceutica
UY27679A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea.
PA8644201A1 (es) Hexadecasacaridos biotinilados, su preparacion y utilizacion
GT200300020A (es) Polimorfismos geneticos en el gen de la preprotaquiquinina
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
AR048068A1 (es) Piperazinas derivadas de urea para el tratamiento de endometriosis
NO20071330L (no) Enzyminhibitor i leukemi
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
MX2007003994A (es) Composici??n farmaceutica para el tratamiento de xeroftalmia y xerostomia.
PE20030732A1 (es) Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios
BRPI0415428A (pt) formulações terapêuticas